Insider Transactions in Q2 2023 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-12.7%
|
$44,255
$5.64 P/Share
|
|
Apr 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+23.01%
|
-
|
|
Apr 14
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-5.13%
|
$6,975
$5.64 P/Share
|
|
Apr 14
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+9.37%
|
-
|
|
Apr 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.51%
|
$6,975
$5.64 P/Share
|
|
Apr 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+8.33%
|
-
|